HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) web only appendix Alert me when this article is cited Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Panés, J. Articles by Ghosh, S. Search for Related Content PubMed PubMed Citation Articles by Panés, J. Articles by Ghosh, S. Topic Collections Relevant Article

The classics in perspective

¹ Department of Gastroenterology, Hospital Clínic Barcelona, CIBER-EHD, Barcelona, Spain
² Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK

Correspondence to:
Correspondence to:
Subrata Ghosh
Professor of Gastroenterology, Imperial College London, Hammersmith Hospital, London W12 0NN, UK; s.ghosh@imperial.ac.uk

Abbreviations: ACCENT, A Crohn’s disease Clinical trial Evaluating infliximab in a New long-term Treatment regimen; CHARM, Crohn’s Trial of the Fully Human Antibody Adalimumab; CLASSIC, CLinical assessment of Adalimumab Safety and efficacy Studied as an Induction therapy in Crohn’s; GAIN, Gauging Adalimumab efficacy in Infliximab Nonresponders; GETAID, Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives; PRECISE, PEGylated antibody fRagment Evaluation in. Crohn’s disease: Safety and Efficacy; SONIC, SONIC (Study Of biologic and Immunomodulator Naive patients in Crohn’s disease; TNF, tumour necrosis factor

Keywords: adalimumab; Anti-TNF therapy; Crohn’s disease; inflammatory bowel disease

The first 150 words of the full text of this article appear below.

With the development and introduction of anti-cytokine therapies as biological agents, our therapeutic approach to Crohn disease and inflammatory diseases in general has dramatically expanded within the past few years. Biological agents technically mean a molecule that is the product of a biological system and functionally that is an agent that targets a specific biological molecule. Gastroenterologists are facing a remarkable wave of new biological therapies for inflammatory bowel diseases (IBD), including anti-tumour necrosis factor (TNF) antibodies (infliximab, adalimumab, certolizumab pegol), an anti-CD3 antibody (visilizumab), an anti-integrin antibody (natalizumab), and an anti-IL-12p40 and anti-IL6 receptor antibody (tocilizumab). Several biological therapies have also proven to be ineffective in large clinical trials, despite good initial promise, such as antibodies against soluble TNF receptors (etanercept, onercept), interleukin-10 and granulocyte–macrophage colony-stimulating factor (sargramostim).

Infliximab, an intravenously administered chimeric monoclonal antibody to TNF, has been for some years the only biological molecule approved . . . [Full text of this article]

Relevant Article

Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial

W J Sandborn, S B Hanauer, P Rutgeerts, R N Fedorak, M Lukas, D G MacIntosh, R Panaccione, D Wolf, J D Kent, B Bittle, J Li, and P F Pollack
Gut 2007 56: 1232-1239. [Abstract] [Full Text] [PDF]